{"id":153220,"date":"2014-05-14T00:00:00","date_gmt":"2014-05-14T00:00:00","guid":{"rendered":"https:\/\/v2.optiknow.ca\/allergan-dit-non-a-valeant-qui-revient-a-la-charge\/"},"modified":"2014-05-14T00:00:00","modified_gmt":"2014-05-14T00:00:00","slug":"allergan-dit-non-a-valeant-qui-revient-a-la-charge","status":"publish","type":"post","link":"https:\/\/v2.optiknow.ca\/fr\/2014\/05\/14\/allergan-dit-non-a-valeant-qui-revient-a-la-charge\/","title":{"rendered":"Allergan dit non \u00e0 Valeant\u0085 qui revient \u00e0 la charge"},"content":{"rendered":"<p>\u00a0<\/p>\n<p>Le conseil d'administration d'Allergan, fabricant des gouttes oculaires Restasis, a officiellement refus\u00e9 l'offre d'achat non sollicit\u00e9e de la pharmaceutique qu\u00e9b\u00e9coise Valeant.<\/p>\n<p class=\"Corps\">\u00a0<\/p>\n<p class=\"Corps\">Allergan soutient que l'offre de 52 G$ en esp\u00e8ces et en actions sous-estime sa valeur en ne refl\u00e9tant pas ses possibilit\u00e9s de croissance. Le conseil d'administration estime que son b\u00e9n\u00e9fice par action augmentera de 20 \u00e0 25 pour cent, et pr\u00e9voit une forte croissance de ses revenus en 2015.<\/p>\n<p class=\"Corps\">\u00a0<\/p>\n<p class=\"Corps\">Dans une lettre envoy\u00e9e \u00e0 son homologue de Valeant, le PDG d'Allergan se demande aussi comment Valeant s'y prendra pour obtenir les r\u00e9ductions de co\u00fbts qu'il envisage sans nuire \u00e0 la viabilit\u00e9 \u00e0 long terme d'Allergan. Valeant estime que l'acquisition permettrait d'\u00e9conomiser 3,3\u00a0G$ dans les co\u00fbts d'exploitation gr\u00e2ce \u00e0 des synergies.<\/p>\n<p class=\"Corps\">\u00a0<\/p>\n<p class=\"Corps\">Loin de renoncer, Valeant est rapidement revenue \u00e0 la charge, affirmant que l'offre serait bonifi\u00e9e. Des d\u00e9tails doivent \u00eatre annonc\u00e9s \u00e0 ce sujet le 28 mai. Par ailleurs, Pershing Square Capital Management, le partenaire de Valeant dans cette offre d'achat, souhaite obtenir la liste compl\u00e8te des actionnaires d'Allergan. Valeant souhaiterait organiser un \u00ab\u00a0r\u00e9f\u00e9rendum\u00a0\u00bb aupr\u00e8s de ces actionnaires, afin de d\u00e9terminer s'ils souhaitent voir les deux entreprises n\u00e9gocier la fusion. Valeant pourrait m\u00eame r\u00e9clamer la tenue d'une assembl\u00e9e extraordinaire pour remplacer certains ou tous les membres du conseil d'administration d'Allergan.<\/p>\n<p><br class=\"Corps\" \/><\/p>\n<p class=\"Corps\">Sources :<\/p>\n<p class=\"Corps\"><a title=\"Allergan dit non \u00e0 Valeant\u0085 qui revient \u00e0 la charge\" href=\"http:\/\/www.lesaffaires.com\/secteurs-d-activite\/sante-pharmaceutique-et-biotechnologies\/allergan-rejette-l-offre-de-valeant\/568801\">http:\/\/www.lesaffaires.com\/secteurs-d-activite\/sante-pharmaceutique-et-biotechnologies\/allergan-rejette-l-offre-de-valeant\/568801<\/a><\/p>\n<p class=\"Corps\"><a title=\"Allergan dit non \u00e0 Valeant\u0085 qui revient \u00e0 la charge\" href=\"http:\/\/eyewiretoday.com\/view.asp?20140512-allergan_rejects_valeant_pharmas_cut_and_slash_takeover\">http:\/\/eyewiretoday.com\/view.asp?20140512-allergan_rejects_valeant_pharmas_cut_and_slash_takeover<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u00a0 Le conseil d'administration d'Allergan, fabricant des gouttes oculaires Restasis, a officiellement refus\u00e9 l'offre d'achat non sollicit\u00e9e de la pharmaceutique qu\u00e9b\u00e9coise Valeant. \u00a0 Allergan soutient que l'offre de 52 G$ [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[23133],"tags":[],"class_list":["post-153220","post","type-post","status-publish","format-standard","hentry","category-nouvelles"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Allergan dit non \u00e0 Valeant\u0085 qui revient \u00e0 la charge - OptikNow<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Allergan dit non \u00e0 Valeant\u0085 qui revient \u00e0 la charge - OptikNow\" \/>\n<meta property=\"og:description\" content=\"\u00a0 Le conseil d&#039;administration d&#039;Allergan, fabricant des gouttes oculaires Restasis, a officiellement refus\u00e9 l&#039;offre d&#039;achat non sollicit\u00e9e de la pharmaceutique qu\u00e9b\u00e9coise Valeant. \u00a0 Allergan soutient que l&#039;offre de 52 G$ [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/v2.optiknow.ca\/fr\/2014\/05\/14\/allergan-dit-non-a-valeant-qui-revient-a-la-charge\/\" \/>\n<meta property=\"og:site_name\" content=\"OptikNow\" \/>\n<meta property=\"article:published_time\" content=\"2014-05-14T00:00:00+00:00\" \/>\n<meta name=\"author\" content=\"Optiknow\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Optiknow\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2014\\\/05\\\/14\\\/allergan-dit-non-a-valeant-qui-revient-a-la-charge\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2014\\\/05\\\/14\\\/allergan-dit-non-a-valeant-qui-revient-a-la-charge\\\/\"},\"author\":{\"name\":\"Optiknow\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#\\\/schema\\\/person\\\/94d0fced8e14590d08b3c02ab7a8c150\"},\"headline\":\"Allergan dit non \u00e0 Valeant\u0085 qui revient \u00e0 la charge\",\"datePublished\":\"2014-05-14T00:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2014\\\/05\\\/14\\\/allergan-dit-non-a-valeant-qui-revient-a-la-charge\\\/\"},\"wordCount\":273,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#organization\"},\"articleSection\":[\"Nouvelles\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2014\\\/05\\\/14\\\/allergan-dit-non-a-valeant-qui-revient-a-la-charge\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2014\\\/05\\\/14\\\/allergan-dit-non-a-valeant-qui-revient-a-la-charge\\\/\",\"url\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2014\\\/05\\\/14\\\/allergan-dit-non-a-valeant-qui-revient-a-la-charge\\\/\",\"name\":\"Allergan dit non \u00e0 Valeant\u0085 qui revient \u00e0 la charge - OptikNow\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#website\"},\"datePublished\":\"2014-05-14T00:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2014\\\/05\\\/14\\\/allergan-dit-non-a-valeant-qui-revient-a-la-charge\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2014\\\/05\\\/14\\\/allergan-dit-non-a-valeant-qui-revient-a-la-charge\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2014\\\/05\\\/14\\\/allergan-dit-non-a-valeant-qui-revient-a-la-charge\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Allergan dit non \u00e0 Valeant\u0085 qui revient \u00e0 la charge\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/\",\"name\":\"OptikNow\",\"description\":\"Canadian Eye Care and Eyewear News for Eye Care Professionals\",\"publisher\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#organization\",\"name\":\"OptikNow\",\"url\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/v2.optiknow.ca\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/cropped-Optik-NOW_RGB.png\",\"contentUrl\":\"https:\\\/\\\/v2.optiknow.ca\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/cropped-Optik-NOW_RGB.png\",\"width\":1181,\"height\":250,\"caption\":\"OptikNow\"},\"image\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#\\\/schema\\\/person\\\/94d0fced8e14590d08b3c02ab7a8c150\",\"name\":\"Optiknow\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g\",\"caption\":\"Optiknow\"},\"sameAs\":[\"https:\\\/\\\/v2.optiknow.ca\"],\"url\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/author\\\/optiknow\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Allergan dit non \u00e0 Valeant\u0085 qui revient \u00e0 la charge - OptikNow","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"Allergan dit non \u00e0 Valeant\u0085 qui revient \u00e0 la charge - OptikNow","og_description":"\u00a0 Le conseil d'administration d'Allergan, fabricant des gouttes oculaires Restasis, a officiellement refus\u00e9 l'offre d'achat non sollicit\u00e9e de la pharmaceutique qu\u00e9b\u00e9coise Valeant. \u00a0 Allergan soutient que l'offre de 52 G$ [&hellip;]","og_url":"https:\/\/v2.optiknow.ca\/fr\/2014\/05\/14\/allergan-dit-non-a-valeant-qui-revient-a-la-charge\/","og_site_name":"OptikNow","article_published_time":"2014-05-14T00:00:00+00:00","author":"Optiknow","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Optiknow","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/v2.optiknow.ca\/fr\/2014\/05\/14\/allergan-dit-non-a-valeant-qui-revient-a-la-charge\/#article","isPartOf":{"@id":"https:\/\/v2.optiknow.ca\/fr\/2014\/05\/14\/allergan-dit-non-a-valeant-qui-revient-a-la-charge\/"},"author":{"name":"Optiknow","@id":"https:\/\/v2.optiknow.ca\/fr\/#\/schema\/person\/94d0fced8e14590d08b3c02ab7a8c150"},"headline":"Allergan dit non \u00e0 Valeant\u0085 qui revient \u00e0 la charge","datePublished":"2014-05-14T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/v2.optiknow.ca\/fr\/2014\/05\/14\/allergan-dit-non-a-valeant-qui-revient-a-la-charge\/"},"wordCount":273,"commentCount":0,"publisher":{"@id":"https:\/\/v2.optiknow.ca\/fr\/#organization"},"articleSection":["Nouvelles"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/v2.optiknow.ca\/fr\/2014\/05\/14\/allergan-dit-non-a-valeant-qui-revient-a-la-charge\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/v2.optiknow.ca\/fr\/2014\/05\/14\/allergan-dit-non-a-valeant-qui-revient-a-la-charge\/","url":"https:\/\/v2.optiknow.ca\/fr\/2014\/05\/14\/allergan-dit-non-a-valeant-qui-revient-a-la-charge\/","name":"Allergan dit non \u00e0 Valeant\u0085 qui revient \u00e0 la charge - OptikNow","isPartOf":{"@id":"https:\/\/v2.optiknow.ca\/fr\/#website"},"datePublished":"2014-05-14T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/v2.optiknow.ca\/fr\/2014\/05\/14\/allergan-dit-non-a-valeant-qui-revient-a-la-charge\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/v2.optiknow.ca\/fr\/2014\/05\/14\/allergan-dit-non-a-valeant-qui-revient-a-la-charge\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/v2.optiknow.ca\/fr\/2014\/05\/14\/allergan-dit-non-a-valeant-qui-revient-a-la-charge\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/v2.optiknow.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Allergan dit non \u00e0 Valeant\u0085 qui revient \u00e0 la charge"}]},{"@type":"WebSite","@id":"https:\/\/v2.optiknow.ca\/fr\/#website","url":"https:\/\/v2.optiknow.ca\/fr\/","name":"OptikNow","description":"Canadian Eye Care and Eyewear News for Eye Care Professionals","publisher":{"@id":"https:\/\/v2.optiknow.ca\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/v2.optiknow.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/v2.optiknow.ca\/fr\/#organization","name":"OptikNow","url":"https:\/\/v2.optiknow.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/v2.optiknow.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/v2.optiknow.ca\/wp-content\/uploads\/2025\/10\/cropped-Optik-NOW_RGB.png","contentUrl":"https:\/\/v2.optiknow.ca\/wp-content\/uploads\/2025\/10\/cropped-Optik-NOW_RGB.png","width":1181,"height":250,"caption":"OptikNow"},"image":{"@id":"https:\/\/v2.optiknow.ca\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/v2.optiknow.ca\/fr\/#\/schema\/person\/94d0fced8e14590d08b3c02ab7a8c150","name":"Optiknow","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g","caption":"Optiknow"},"sameAs":["https:\/\/v2.optiknow.ca"],"url":"https:\/\/v2.optiknow.ca\/fr\/author\/optiknow\/"}]}},"_links":{"self":[{"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/posts\/153220","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/comments?post=153220"}],"version-history":[{"count":0,"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/posts\/153220\/revisions"}],"wp:attachment":[{"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/media?parent=153220"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/categories?post=153220"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/tags?post=153220"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}